The Patent Finder

OliX Pharmaceuticals, Inc.

18 patents currently held · Updated Nov 16, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Sep 2031
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 28, 2026
    The maintenance fee for Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor (US 10,301,628) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
  • 1 fee due Jan 23, 2027
    The maintenance fee for Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1 (US 10,358,648) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
  • 2 fees due Jun 24 to 30, 2027 · next Jun 24
  • 1 fee due Sep 17, 2027
    The maintenance fee for Treatment of Age-Related Macular Degeneration Using RNA Complexes That Target MYD88 or TLR3 (US 10,590,423) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,214,744Nucleic acid molecules inducing RNA interference, and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,829,760Nucleic acid molecules inducing RNA interference, and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,637,742Nucleic acid molecules inducing RNA interference, and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,125,362RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,883,105RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,064,801RNA complexes that inhibit melanin production
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,512,600RNA complexes that inhibit melanin production
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,059,949Treatment of Age-Related Macular Degeneration Using RNA Complexes That Target MYD88 or TLR3
In force
 · High confidence
In forceHigh confidence
US 10,590,423Treatment of Age-Related Macular Degeneration Using RNA Complexes That Target MYD88 or TLR3
In force
 · Low confidence
In forceLow confidence
US 10,358,648Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 18 patents shown.
Pro members see all 18.
Pro members: see all 18 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 3 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited